Unleashing new MTDL AChE and BuChE inhibitors as potential anti-AD therapeutic agents: In vitro, in vivo and in silico studies
- 21 April 2024
- journal article
- research article
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 268 (Pt 1) , 131740
Abstract
No abstract availableKeywords
Funding Information
- STDF
This publication has 31 references indexed in Scilit:
- The biological activities of butyrylcholinesterase inhibitorsBiomedicine & Pharmacotherapy, 2022
- Design, synthesis, and evaluation of N-benzylpyrrolidine and 1,3,4-oxadiazole as multitargeted hybrids for the treatment of Alzheimer’s diseaseBioorganic Chemistry, 2021
- In vitro and in vivo evaluation of the neuroprotective activity of Uncaria hirsuta HavilandJournal of Food and Drug Analysis, 2020
- Effects of vitamin D in an animal model of Alzheimer’s disease: behavioral assessment with biochemical investigation of Hippocampus and serumMetabolic Brain Disease, 2019
- Design and development of 1,3,4-oxadiazole derivatives as potential inhibitors of acetylcholinesterase to ameliorate scopolamine-induced cognitive dysfunctionsBioorganic Chemistry, 2019
- Crosstalk between mitochondrial dysfunction, oxidative stress, and age related neurodegenerative disease: Etiologies and therapeutic strategiesLife Sciences, 2019
- A molecular approach in drug development for Alzheimer’s diseaseBiomedicine & Pharmacotherapy, 2018
- Alzheimer's disease drug discovery: in vivo screening using Caenorhabditis elegans as a model for β-amyloid peptide-induced toxicityDrug Discovery Today: Technologies, 2012
- Caco-2 permeability of weakly basic drugs predicted with the Double-Sink PAMPA methodEuropean Journal of Pharmaceutical Sciences, 2005
- Alzheimer DiseaseJAMA, 2002